Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Lucidone suppresses hepatitis C virus replication by Nrf2-mediated heme oxygenase-1 induction.

Chen WC, Wang SY, Chiu CC, Tseng CK, Lin CK, Wang HC, Lee JC.

Antimicrob Agents Chemother. 2013 Mar;57(3):1180-91. doi: 10.1128/AAC.02053-12. Epub 2012 Dec 17.

2.

Andrographolide exerts anti-hepatitis C virus activity by up-regulating haeme oxygenase-1 via the p38 MAPK/Nrf2 pathway in human hepatoma cells.

Lee JC, Tseng CK, Young KC, Sun HY, Wang SW, Chen WC, Lin CK, Wu YH.

Br J Pharmacol. 2014 Jan;171(1):237-52. doi: 10.1111/bph.12440.

3.

Sulforaphane Suppresses Hepatitis C Virus Replication by Up-Regulating Heme Oxygenase-1 Expression through PI3K/Nrf2 Pathway.

Yu JS, Chen WC, Tseng CK, Lin CK, Hsu YC, Chen YH, Lee JC.

PLoS One. 2016 Mar 29;11(3):e0152236. doi: 10.1371/journal.pone.0152236. eCollection 2016.

4.

Lucidone protects human skin keratinocytes against free radical-induced oxidative damage and inflammation through the up-regulation of HO-1/Nrf2 antioxidant genes and down-regulation of NF-κB signaling pathway.

Kumar KJ, Yang HL, Tsai YC, Hung PC, Chang SH, Lo HW, Shen PC, Chen SC, Wang HM, Wang SY, Chou CW, Hseu YC.

Food Chem Toxicol. 2013 Sep;59:55-66. doi: 10.1016/j.fct.2013.04.055. Epub 2013 May 24.

PMID:
23712098
5.

Biliverdin inhibits hepatitis C virus nonstructural 3/4A protease activity: mechanism for the antiviral effects of heme oxygenase?

Zhu Z, Wilson AT, Luxon BA, Brown KE, Mathahs MM, Bandyopadhyay S, McCaffrey AP, Schmidt WN.

Hepatology. 2010 Dec;52(6):1897-905. doi: 10.1002/hep.23921.

6.

Restoration of the activated Rig-I pathway in hepatitis C virus (HCV) replicon cells by HCV protease, polymerase, and NS5A inhibitors in vitro at clinically relevant concentrations.

Kalkeri G, Lin C, Gopilan J, Sloan K, Rijnbrand R, Kwong AD.

Antimicrob Agents Chemother. 2013 Sep;57(9):4417-26. doi: 10.1128/AAC.00399-13. Epub 2013 Jul 8.

7.

Heme oxygenase-1 suppresses hepatitis C virus replication and increases resistance of hepatocytes to oxidant injury.

Zhu Z, Wilson AT, Mathahs MM, Wen F, Brown KE, Luxon BA, Schmidt WN.

Hepatology. 2008 Nov;48(5):1430-9. doi: 10.1002/hep.22491.

8.

Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes.

Shan Y, Zheng J, Lambrecht RW, Bonkovsky HL.

Gastroenterology. 2007 Oct;133(4):1166-74. Epub 2007 Aug 3.

9.

Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication.

Friborg J, Levine S, Chen C, Sheaffer AK, Chaniewski S, Voss S, Lemm JA, McPhee F.

Antimicrob Agents Chemother. 2013 Mar;57(3):1312-22. doi: 10.1128/AAC.02239-12. Epub 2012 Dec 28.

10.

Restoration of type I interferon expression by heme and related tetrapyrroles through inhibition of NS3/4A protease.

Zhu Z, Mathahs MM, Schmidt WN.

J Infect Dis. 2013 Nov 15;208(10):1653-63. doi: 10.1093/infdis/jit338. Epub 2013 Jul 29.

PMID:
23901085
11.

The heme oxygenase 1 product biliverdin interferes with hepatitis C virus replication by increasing antiviral interferon response.

Lehmann E, El-Tantawy WH, Ocker M, Bartenschlager R, Lohmann V, Hashemolhosseini S, Tiegs G, Sass G.

Hepatology. 2010 Feb;51(2):398-404. doi: 10.1002/hep.23339.

PMID:
20044809
12.

Matrix conditions and KLF2-dependent induction of heme oxygenase-1 modulate inhibition of HCV replication by fluvastatin.

Wuestenberg A, Kah J, Singethan K, Sirma H, Keller AD, Rosal SR, Schrader J, Loscher C, Volz T, Bartenschlager R, Lohmann V, Protzer U, Dandri M, Lohse AW, Tiegs G, Sass G.

PLoS One. 2014 May 6;9(5):e96533. doi: 10.1371/journal.pone.0096533. eCollection 2014.

13.

Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.

Qing J, Luo R, Wang Y, Nong J, Wu M, Shao Y, Tang R, Yu X, Yin Z, Sun Y.

Antiviral Res. 2016 Feb;126:43-54. doi: 10.1016/j.antiviral.2015.12.010. Epub 2015 Dec 24.

PMID:
26724382
14.

Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451.

Yang H, Robinson M, Corsa AC, Peng B, Cheng G, Tian Y, Wang Y, Pakdaman R, Shen M, Qi X, Mo H, Tay C, Krawczyk S, Sheng XC, Kim CU, Yang C, Delaney WE 4th.

Antimicrob Agents Chemother. 2014;58(2):647-53. doi: 10.1128/AAC.00487-13. Epub 2013 Aug 12.

15.

Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.

Berger C, Romero-Brey I, Radujkovic D, Terreux R, Zayas M, Paul D, Harak C, Hoppe S, Gao M, Penin F, Lohmann V, Bartenschlager R.

Gastroenterology. 2014 Nov;147(5):1094-105.e25. doi: 10.1053/j.gastro.2014.07.019. Epub 2014 Jul 18.

16.

Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle.

McGivern DR, Masaki T, Lovell W, Hamlett C, Saalau-Bethell S, Graham B.

J Virol. 2015 May;89(10):5362-70. doi: 10.1128/JVI.03188-14. Epub 2015 Mar 4.

17.

SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells.

Malcolm BA, Liu R, Lahser F, Agrawal S, Belanger B, Butkiewicz N, Chase R, Gheyas F, Hart A, Hesk D, Ingravallo P, Jiang C, Kong R, Lu J, Pichardo J, Prongay A, Skelton A, Tong X, Venkatraman S, Xia E, Girijavallabhan V, Njoroge FG.

Antimicrob Agents Chemother. 2006 Mar;50(3):1013-20.

18.

Inhibition of protease-inhibitor-resistant hepatitis C virus replicons and infectious virus by intracellular intrabodies.

Gal-Tanamy M, Zemel R, Bachmatov L, Jangra RK, Shapira A, Villanueva RA, Yi M, Lemon SM, Benhar I, Tur-Kaspa R.

Antiviral Res. 2010 Oct;88(1):95-106. doi: 10.1016/j.antiviral.2010.08.001. Epub 2010 Aug 10.

19.
20.

Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227).

Seiwert SD, Andrews SW, Jiang Y, Serebryany V, Tan H, Kossen K, Rajagopalan PT, Misialek S, Stevens SK, Stoycheva A, Hong J, Lim SR, Qin X, Rieger R, Condroski KR, Zhang H, Do MG, Lemieux C, Hingorani GP, Hartley DP, Josey JA, Pan L, Beigelman L, Blatt LM.

Antimicrob Agents Chemother. 2008 Dec;52(12):4432-41. doi: 10.1128/AAC.00699-08. Epub 2008 Sep 29.

Supplemental Content

Support Center